SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness
The Cox regression analysis for time to hospital admission found that S gene-positive cases were associated with an increased risk of COVID-19 hospital admission: hazard ratio (HR) 1·85 (95% CI 1·39–2·47) when compared to S gene-negative cases, after adjusting for age, sex, deprivation, temporal tre...
Saved in:
| Published in: | The Lancet (British edition) Vol. 397; no. 10293; pp. 2461 - 2462 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
Elsevier Ltd
26.06.2021
Elsevier Limited |
| Subjects: | |
| ISSN: | 0140-6736, 1474-547X, 1474-547X |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The Cox regression analysis for time to hospital admission found that S gene-positive cases were associated with an increased risk of COVID-19 hospital admission: hazard ratio (HR) 1·85 (95% CI 1·39–2·47) when compared to S gene-negative cases, after adjusting for age, sex, deprivation, temporal trend, and comorbidities. The corresponding hazard ratio for risk of hospital admission for S gene-positive cases was 0·38 (95% CI 0·24–0·58), with an interaction test p value of 0·19, suggesting that there was no evidence of a differential vaccine effect on hospital admissions among those first testing positive (appendix p 4). Considering the whole population cohort (rather than just hospital cases), the test-negative analysis to estimate vaccine effectiveness in preventing RT-PCR-confirmed SARS-CoV-2 infection showed that, compared to those unvaccinated, at least 14 days after the second dose, BNT162b2 (Pfizer–BioNTech vaccine) offered very good protection: 92% (95% CI 90–93) S gene-negative, 79% (75–82) S gene-positive. |
|---|---|
| Bibliography: | SourceType-Scholarly Journals-1 ObjectType-Correspondence-1 content type line 14 content type line 23 |
| ISSN: | 0140-6736 1474-547X 1474-547X |
| DOI: | 10.1016/S0140-6736(21)01358-1 |